Koneksa reports positive topline data from Parkinson’s digital measures study

Koneksa Health said its 12-month KH007 observational study met its primary compliance endpoint in Parkinson’s disease, with participants sustaining high engagement across a demanding digital assessment battery. The results bolster the company’s integrated measurement platform as it prepares additional analyses on validity, reliability and responsiveness.

Why it matters: - KH007 offers evidence that patients with Parkinson’s disease can stay engaged with a high-burden digital study protocol for 12 months. - The result supports the use of digital biomarkers and multi-modal measurement in longer clinical development programs. - Koneksa says the findings also reinforce its syndicated, precompetitive study model for biomarker validation.

What happened: - Koneksa Health announced positive topline results from KH007, a 12-month observational study of digital measures of Parkinson’s disease progression. - The study met its primary compliance endpoint. - Mean participant compliance had a 95% confidence interval of 80% to 88%, above the predefined 75% threshold on the lower bound. - Participants completed 11 motor tasks, four speech tasks and the Movement Disorder Society Unified Parkinson’s Disease Rating Scale electronic patient-reported outcome across the study. - The study ran amid individualized schedules, protocol amendments and medication changes. - Koneksa conducted the study with Merck and Regeneron. - The study enrolled 82 participants with Parkinson’s disease out of 100 screened. - Seventy-three participants completed the full one-year study.

The details: - KH007 evaluated an integrated measurement platform rather than a single device or algorithm. - The platform combined a mobile application, wearables, passive sensors, active motor assessments, speech assessments and electronic patient-reported outcomes. - The design paired point-in-time task-based data with continuous passive monitoring. - Koneksa said the goal was to capture a more comprehensive and interpretable view of disease progression. - Parkinson’s disease affects more than 10 million people worldwide and can cause progressive motor and non-motor symptoms that affect daily function and quality of life. - Koneksa is finalizing additional analyses on validity, reliability and responsiveness to change. - The company expects to share those results when they are available. - Koneksa’s business covers intelligent software, measurement science and data services, including endpoint strategy, digital biomarker development, biometrics, statistical programming and regulatory submission support. - The company says its approach is designed to integrate physiological, clinical and digital signals to reduce variability and clarify treatment effects. - More information is available in Koneksa’s company announcement. - Koneksa also shared social links for LinkedIn, YouTube and X.

Between the lines: - The topline result addresses a key practical question in digital clinical research: whether participants can sustain repeated measurement over a long period. - The study’s completion rate suggests the protocol was demanding but workable in a real-world research setting. - The collaboration with large pharmaceutical partners gives the data added relevance for future drug-development programs. - Daniel Claassen of the Huntington Study Group said the result suggests the bigger bottleneck may be measuring change over time, not patient willingness to participate. - David Lynch, Koneksa’s CEO, said the study was meant to test whether the measurement platform could withstand an extended clinical trial and support a shared dataset model.

What's next: - Koneksa will complete and release the remaining analyses on validity, reliability and responsiveness. - Those follow-up results will show whether the digital measures are not only feasible but also scientifically robust enough for broader use. - The company is likely to use KH007 as support for future validation and adoption of digital biomarkers across drug development.

The bottom line: - KH007’s main message is simple: patients with Parkinson’s disease can stick with a complex digital study long enough to generate usable longitudinal data, which is a key step for expanding digital measurement in clinical trials.